Bond advises Xeltis again on a new financing by the European Investment Bank (EIB)

Bond advised Xeltis in connection with a new financing by the European Investment Bank (EIB) for an amount up to €37.5m, consisting of €10m upfront with optionality to further increase by an additional €27.5m, supported under the European Commission’s Invest EU programme.

Furtmore Xeltis attracted a €10m investment from existing shareholders including EQT Life Sciences (EQT) and Invest-NL.

The proceeds raised will be used to advance aXess into commercialization, including upscaling production and hiring, and supporting the continued development of its broader pipeline.
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. Xeltis seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company’s proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient’s own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place. Xeltis’ most advanced product currently under clinical development is aXessTM, an implantable blood vessel for hemodialysis vascular access. Xeltis’ groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases.

For more information, please refer to:

Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market